A Phase 3 interventional study of Idelalisib and Chlorambucil in Chronic Lymphocytic Leukemia, sponsored by Gilead Sciences. Terminated at 18 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 16th largest by enrollment, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 14th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 8 · Phase 4 1
First in 2008; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 102 across the 25 interventional studies. Of the 22 that completed or were terminated, 21 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 7 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences: none open now, none under way, none of them phase 3. Of 32 finished, 22 (69%) have results posted.
Among the 36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences, this one is the 18th largest by enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2015, is one of 9 in phase 3, and was the 26th registered.
Gilead Sciences’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 36 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effects of idelalisib with obinutuzumab versus the combination of chlorambucil and obinutuzumab on progression-free survival (PFS) in participants with previously untreated chronic lymphocytic leukemia (CLL).
An increased rate of deaths and serious adverse events (SAEs) among participants with front-line CLL and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated those studies in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA). All front-line studies of idelalisib, including this study, were also terminated.
Key Inclusion Criteria:
Not a candidate for fludarabine therapy based on either:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks. Following 4 weeks of treatment, safety data will be reviewed by an independent data monitoring committee (DMC). If acceptable tolerability is observed, the randomized portion of the study will begin.
Drug: Idelalisib · Drug: Obinutuzumab
Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks.
Drug: Idelalisib · Drug: Obinutuzumab
Participants will receive obinutuzumab over 21 weeks and chlorambucil over 23 weeks.
Drug: Chlorambucil · Drug: Obinutuzumab
150 mg tablet administered orally twice daily
Also known as: GS-1101, CAL-101, Zydelig®
2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses
1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
Progression-Free Survival
Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an independent review committee (IRC).
Time frame: Up to 11 months
Overall Response Rate
Overall response rate (ORR) is defined as the proportion of participants who achieve a confirmed complete or partial response. ORR was to be assessed by an IRC.
Time frame: Up to 11 months
Nodal Response Rate
Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Nodal response rate was to be assessed by an IRC.
Time frame: Up to 11 months
Complete Response Rate
Complete response rate is defined as the proportion of participants who achieve a confirmed complete response. Complete response rate was to be assessed by an IRC.
Time frame: Up to 11 months
Overall Survival
Overall survival is defined as the interval from randomization to death from any cause. Overall survival was to be assessed by an IRC.
Time frame: Up to 11 months
Minimal Residual Disease Negativity Rate at Week 36
Minimal residual disease (MRD) negativity rate is defined as the proportion of participants with MRD \< 10\^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation. For participants receiving the final dose of obinutuzumab after the original scheduled date, the MRD assessment was performed no less than 12 weeks after the last dose of obinutuzumab. MRD negativity rate was to be assessed by an IRC.
Time frame: Up to 11 months
Participants were enrolled at study sites in Australia, Europe, and North America. The first participant was screened on 21 April 2015. The last study visit occurred on 13 May 2016.
| Milestone | Safety Run-In: Idelalisib+Obinutuzumab | Randomized: Idelalisib+Obinutuzumab | Randomized: Obinutuzumab+Chlorambucil |
|---|---|---|---|
| Started | 8 | 25 | 24 |
| Completed | 0 | 0 | 0 |
| Not completed | 8 | 25 | 24 |
| Withdrew: Withdrew consent | 1 | 1 | 1 |
| Withdrew: Study terminated by sponsor | 7 | 24 | 22 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an independent review committee (IRC).
No measurements were reported for this outcome.
Overall response rate (ORR) is defined as the proportion of participants who achieve a confirmed complete or partial response. ORR was to be assessed by an IRC.
No measurements were reported for this outcome.
Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Nodal response rate was to be assessed by an IRC.
No measurements were reported for this outcome.
Complete response rate is defined as the proportion of participants who achieve a confirmed complete response. Complete response rate was to be assessed by an IRC.
No measurements were reported for this outcome.
Overall survival is defined as the interval from randomization to death from any cause. Overall survival was to be assessed by an IRC.
No measurements were reported for this outcome.
Minimal residual disease (MRD) negativity rate is defined as the proportion of participants with MRD \< 10\^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation. For participants receiving the final dose of obinutuzumab after the original scheduled date, the MRD assessment was performed no less than 12 weeks after the last dose of obinutuzumab. MRD negativity rate was to be assessed by an IRC.
No measurements were reported for this outcome.
Collected over Baseline up to the last dose date plus 30 days (maximum: 12 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Run-In: Idelalisib+Obinutuzumab | 0/8 (0%) | 2/8 (25%) | 8/8 (100%) |
| Randomized: Idelalisib+Obinutuzumab | 0/24 (0%) | 12/24 (50%) | 19/24 (79.2%) |
| Randomized: Obinutuzumab+Chlorambucil | 0/23 (0%) | 8/23 (34.8%) | 17/23 (73.9%) |
| Event | Safety Run-In: Idelalisib+Obinutuzumab | Randomized: Idelalisib+Obinutuzumab | Randomized: Obinutuzumab+Chlorambucil |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/8 | 0/24 | 0/23 |
| LeukoencephalopathyNervous system disorders | 1/8 | 0/24 | 0/23 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 2/24 | 1/23 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/8 | 2/24 | 0/23 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/8 | 1/24 | 1/23 |
| HypersensitivityImmune system disorders | 0/8 | 0/24 | 1/23 |
| Secondary immunodeficiencyImmune system disorders | 0/8 | 0/24 | 1/23 |
| GastroenteritisInfections and infestations | 0/8 | 0/24 | 1/23 |
| Herpes zosterInfections and infestations | 0/8 | 0/24 | 1/23 |
| PneumoniaInfections and infestations | 0/8 | 0/24 | 1/23 |
| Event | Safety Run-In: Idelalisib+Obinutuzumab | Randomized: Idelalisib+Obinutuzumab | Randomized: Obinutuzumab+Chlorambucil |
|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 7/8 | 5/24 | 1/23 |
| Aspartate aminotransferase increasedInvestigations | 7/8 | 5/24 | 1/23 |
| Infusion related reactionInjury, poisoning and procedural complications | 2/8 | 3/24 | 14/23 |
| NeutropeniaBlood and lymphatic system disorders | 4/8 | 6/24 | 9/23 |
| DiarrhoeaGastrointestinal disorders | 4/8 | 4/24 | 1/23 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/8 | 2/24 | 1/23 |
| AnaemiaBlood and lymphatic system disorders | 2/8 | 6/24 | 2/23 |
| ConstipationGastrointestinal disorders | 2/8 | 2/24 | 1/23 |
| NauseaGastrointestinal disorders | 2/8 | 2/24 | 4/23 |
| Influenza like illnessGeneral disorders | 2/8 | 0/24 | 0/23 |
Intent-to-Treat Analysis Set: participants who were randomized regardless of whether participants received any study drug(s), or received a different regimen from the regimen to which they were randomized.
| Age, Continuous(years) | Safety Run-In: Idelalisib+Obinutuzumab | Randomized: Idelalisib+Obinutuzumab | Randomized: Obinutuzumab+Chlorambucil | Total |
|---|---|---|---|---|
| Mean | 67.1 ± 8.10 | 72.2 ± 8.23 | 71.1 ± 6.84 | 71.1 ± 7.70 |
| Sex: Female, Male(Participants) | Safety Run-In: Idelalisib+Obinutuzumab | Randomized: Idelalisib+Obinutuzumab | Randomized: Obinutuzumab+Chlorambucil | Total |
|---|---|---|---|---|
| Female | 3 | 8 | 9 | 20 |
| Male | 5 | 17 | 15 | 37 |
| Race/Ethnicity, Customized(Participants) | Safety Run-In: Idelalisib+Obinutuzumab | Randomized: Idelalisib+Obinutuzumab | Randomized: Obinutuzumab+Chlorambucil | Total |
|---|---|---|---|---|
| Black or African American | 1 | 0 | 0 | 1 |
| White | 7 | 22 | 21 | 50 |
| Other | 0 | 1 | 0 | 1 |
| Not Permitted | 0 | 2 | 3 | 5 |
| Region of Enrollment(participants) | Safety Run-In: Idelalisib+Obinutuzumab | Randomized: Idelalisib+Obinutuzumab | Randomized: Obinutuzumab+Chlorambucil | Total |
|---|---|---|---|---|
| Canada | 1 | 1 | 0 | 2 |
| Belgium | 0 | 1 | 1 | 2 |
| United States | 5 | 3 | 4 | 12 |
| Poland | 2 | 14 | 12 | 28 |
| United Kingdom | 0 | 1 | 2 | 3 |
| France | 0 | 3 | 2 | 5 |
| Australia | 0 | 1 | 3 | 4 |
| Spain | 0 | 1 | 0 | 1 |
| Rai Stage(Participants) | Safety Run-In: Idelalisib+Obinutuzumab | Randomized: Idelalisib+Obinutuzumab | Randomized: Obinutuzumab+Chlorambucil | Total |
|---|---|---|---|---|
| Stage I-II | 3 | 11 | 9 | 23 |
| Stage III-IV | 5 | 14 | 15 | 34 |
| IgHV Mutation(Participants) | Safety Run-In: Idelalisib+Obinutuzumab | Randomized: Idelalisib+Obinutuzumab | Randomized: Obinutuzumab+Chlorambucil | Total |
|---|---|---|---|---|
| Unmutated | 5 | 16 | 17 | 38 |
| Mutated | 3 | 9 | 7 | 19 |
| 17p Deletion in CLL Cells(Participants) | Safety Run-In: Idelalisib+Obinutuzumab | Randomized: Idelalisib+Obinutuzumab | Randomized: Obinutuzumab+Chlorambucil | Total |
|---|---|---|---|---|
| Present | 0 | 3 | 3 | 6 |
| Absent | 8 | 22 | 21 | 51 |
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
No publications or documents are linked to this record.
Ran from Apr 2015 to primary completion in May 2016, 12 months.
Results were first posted in Jun 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib
Leukemia, Lymphocytic, Chronic, B-Cell →